Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2008-07-29
2008-07-29
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C424S046000, C424S489000, C540S002000, C540S007000
Reexamination Certificate
active
07405207
ABSTRACT:
This invention relates to a sealed container containing a powder formulation comprising a dehydroepiandrosterone, its analogue(s) or salt(s) by itself or with a pharmaceutically or veterinarily acceptable carrier or diluent, and having a particle size of about 0.1 μm to about 100 μm. The formulation can be used to treat or prevent asthma, chronic obstructive pulmonary disease, lung inflammation, and other respiratory diseases or conditions. The formulation may be prepared by jet milling, and may be delivered through the respiratory tract or other routes using a nebulizer. The sealed container is provided in a device and/or a therapeutic kit.
REFERENCES:
patent: 3943987 (1976-03-01), Rossi
patent: 4379842 (1983-04-01), Fujiwara et al.
patent: 4393066 (1983-07-01), Garrett et al.
patent: 4499064 (1985-02-01), Shive
patent: 4518595 (1985-05-01), Coleman et al.
patent: 4575498 (1986-03-01), Holmes et al.
patent: 4628052 (1986-12-01), Peat
patent: 4789669 (1988-12-01), Sugimoto et al.
patent: 4920115 (1990-04-01), Nestler et al.
patent: 4931441 (1990-06-01), Lawrence
patent: 4985443 (1991-01-01), Montes
patent: 5021417 (1991-06-01), Prost
patent: 5059595 (1991-10-01), Le Grazie
patent: 5077284 (1991-12-01), Loria et al.
patent: 5110810 (1992-05-01), Eich et al.
patent: 5118505 (1992-06-01), Költringer
patent: 5162198 (1992-11-01), Eich et al.
patent: 5173488 (1992-12-01), Haeger
patent: 5177076 (1993-01-01), Nijkerk et al.
patent: 5266312 (1993-11-01), Leung et al.
patent: 5270305 (1993-12-01), Palmer
patent: 5347005 (1994-09-01), Mueller et al.
patent: 5407684 (1995-04-01), Loria et al.
patent: 5407927 (1995-04-01), Morales et al.
patent: 5489581 (1996-02-01), Daynes et al.
patent: 5527789 (1996-06-01), Nyce
patent: 5532230 (1996-07-01), Daynes et al.
patent: 5538734 (1996-07-01), Le Grazie
patent: 5583126 (1996-12-01), Daynes et al.
patent: 5635496 (1997-06-01), Daynes et al.
patent: 5686438 (1997-11-01), Daynes et al.
patent: 5703063 (1997-12-01), Chasalow et al.
patent: 5767278 (1998-06-01), Gaeta et al.
patent: 5811418 (1998-09-01), Daynes et al.
patent: 5859000 (1999-01-01), Dowell et al.
patent: 5861391 (1999-01-01), Yen et al.
patent: 5948434 (1999-09-01), Labrie
patent: 6093706 (2000-07-01), Zeligs
patent: 2002/0032160 (2002-03-01), Nyce
patent: 2002/0042401 (2002-04-01), Ferguson et al.
patent: 2003/0013772 (2003-01-01), Murphy et al.
patent: 2003/0138434 (2003-07-01), Campbell et al.
patent: 2003/0139331 (2003-07-01), Martin et al.
patent: 2003/0216329 (2003-11-01), Robinson et al.
patent: WO 00/54763 (2000-07-01), None
patent: WO 01/015745 (2000-07-01), None
patent: WO 02/069955 (2000-07-01), None
patent: WO 03/072572 (2000-07-01), None
patent: WO 93/16704 (2000-07-01), None
patent: WO 96/16680 (2000-07-01), None
patent: WO 97/48367 (2000-07-01), None
patent: WO 98/03180 (2000-07-01), None
Araneo et al., “Dehydroepiandrosterone Reduces Progressive Dermal Ishemia Caused by Thermal Injury,”J. Surg. Res. 59(2):250-62 (1995).
Bonnett et al., “Dehydroepiandrosteron (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension,”PNAS100(16):9488-93 (2003).
Budavari, The Merck Index 11th ed., 1989, pp. 660-661, monograph 4141.
Coleridge et al., “Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators”,Aust. N.Z. J. Med. 23:348-54 (1993).
Dashtaki et al., “Dehydroepiandrosterone and Analogs Inhibit DNA Binding of AP-1 and Airways Smooth Muscle Proliferation,”J. Pharmacol. EXD. Thera. 285(2):876-83 (1998).
Dompeling et al., “Treatment with Inhaled Steroids in Asthma and Chronic Bronchitis Long Term Compliance and Inhaler Technique”,Family Practice9(2):161-6 (1992).
Dunn, et al., “Dehydroepiandrosterone sulphate concentrations in asthmatic patients: pilot study,”N.Z. J. Med. 97(768):805-8 (1984).
Dworksi et al., “Conspectus: Inhaled Steroids in Asthma”,Comprehensive Therapy, 18,3 (1992).
Fehér et al., “Adrenocortical Function in Bronchial Asthma”,Acta Medica Hungarica40(2-3):125-32 (1983).
Fehér, et al., “Dehydroepiandrosterone Therapy of Patients with Corticosteroid Dependent Bronchial Asthma,”Natl. Institute of Rheumatism and Physiotherapy, in XIII Congress of the European Academy of Allergology and Clinical Immunology, eds. (Saba, et al., Debrecen Hungary (1986).
Hampl et al., “Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertensions in rats,”J. Eur. Respir, 21:862-5 (2003).
Holzmann et al., “Therapy of Psoriasis with Dehydroepiandrosterone-Enanthate. II. Intramuscular Depot Application of 300 mg”,Arch. Dermatol. Forsch. 247(1):23-8 (1973) (German with English Abstract).
Hummel et al., “Comparison of oral-steroids sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma”,The Lancet, 340(8834/8835):1483-7 (1992).
Ishihara et al., “Gas Chromatographic Determination of Degradation Products and Stability of Dehydroepiandrosterone Sulfate in Aqueous Solution,”Drug Development and Industrial Pharmacy. 1979; 5(9): 263-275.
Itagaki et al., “Effect of Cortisol on the Release of Human Decidual”, Caplus, 114875 (1991) (Japanese with English Abstract).
Koó et al., “Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchical Asthma”,Orvosi Hetilap128(38):1995-7 (1987) (English translation).
Lejeune, “Pathogenesis of Mental Impairment in Tristomy 21”,Annales de Genetique, 34(2): 55-64 (1991) (French with English Abstract).
Mileva et al., “Andostenedione, DHEA sulfact, cortisol, aldosterone and testosterone in asthmatic patients”, 07608054 (1990) (Russian with English Abstract).
Nakagawa, et al., The Properties of Water of Crystallization of Sodium Prasterone Sulfate,Chem. Pharm. Bull29(5): 1466-9 (1981).
Nakagawa, et al., “The of Grinding and Drying on the Solid State Stability of Sodium Prasterone Sulfate,”Chem. Pharm. Bull30(1):242-8 (1982).
Pashko et al., “Inhibition of 7,12-dimethylbenz(a)anthracene-induced Skin Papillomas and Carcinomas by Dephydroepiandrosterone and 3-beta-methylandrost-5-en-17-one in mice”,Cancer Res. 45(1):164-6 (1985).
Peeters et al., “Differences in Purine Metabolism in Patients with Down's Syndrome”,J. Intellect. Diabil. Res. 37:471 (1993). Abstract.
Reed, “Aerosol Steroids as Primary Treatment of Mild Asthma”,New England J. Med. 325(6):425-6 (1991).
Rowe et al., “Effectiveness of Steroid Therapy in Acut Exacerbations of Asthma: A Meta-analysis”,Amer. J. Emergency Med. 10(4):301-10 (1992).
Sasaki et al., “Cervical Ripening with Dehydroepiandrosterone Sulphate”,Br. J. Obstet. Gynaecol. 89(3):195-8, (1982).
Sciarra et al., “Aerosols”,Remington's Pharmaceutical Sciences, 18thed . (1990), Eds. Gennaro et al., pp. 1873-1875 and 1694-1712.
Sharma et al., “Screening of potential chemopreventive agents using biochemical markers of carcinogenesis”,Cancer Res. 54(22):5848-55 (1994).
Shomali, “The Use of Anti-Aging Hormones Melatonin. Growth Hormone, Testosterone, and Dehydroepiandrosterone: Consumer Enthusiam for Unproven Therapies”,Md. Med. J. 46(4):181-6 (1997).
Sonka et al., “Gout and Dehydroepiandrosterone: 3. DHEA Administration”,Endokrynologia Polska24(3):209-18 (1973).
Sur et al., “Double-blind trial pyroxidine (vitamin B6) in the treatment of steroid-dependent asthma”,Ann. Allergy. 70:147-52 (1993).
Schwartz et al., “Inhibition of 7,12-dimethylbenz[a]anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehvdroepiandrosterone,”Carcinoaenesis2(12):1335-7 (1981).
Van de Graaf et al., “Respiratory Membrane Permeability and Bronchial Hyperreactivity in Patients with Stable Asthma: Effects of Therapy with Inhaled Steroids”,Bro
Johnson Keith A.
Leonard Sherry A.
Acevedo James H Alstrum
Epigenesis Pharmaceuticals, Inc.
Halluin Albert P.
Reamey Robert H.
Richter Johann
LandOfFree
Nebulizer formulations of dehydroepiandrosterone and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nebulizer formulations of dehydroepiandrosterone and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nebulizer formulations of dehydroepiandrosterone and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2800248